SOX与XELOX方案对术后复发性胃癌患者血清肿瘤标志物、生存期及耐受性的比较研究  

Comparison of Blood Tumor Markers Levels,Survival Time and Tolerance between SOX and XELOX Regimen in Patients with Recurrence after Gastric Cancersurgery

作　　者：蒋冬 孙晓[1] 樊宏伟[1] JIANG Dong;SUN Xiao;FAN Hongwei(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2021年第5期831-835,共5页The Practical Journal of Cancer

摘　　要：目的探讨替吉奥联合奥沙利铂(SOX)与卡培他滨联合奥沙利铂(XELOX)化疗方案应用于术后复发性胃癌患者的血肿瘤标志物水平、生存期及耐受性差异。方法回顾性分析192例术后复发性胃癌患者临床资料,采用SOX方案者纳入S组(n=98),采用XELOX方案者纳入X组(n=94)。比较治疗前及治疗6个周期后,两组血清肿瘤标志物[糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)]、生活质量[胃癌患者生活质量问卷(QLQ-STO22)]变化,分析两组治疗效果、无进展生存期(PFS)及6个周期内不良反应严重程度差异。结果治疗6个周期后,两组ORR与死亡率比较均无统计学意义(P>0.05);两组血清CA125、CA19-9、CEA水平均较治疗前有显著下降(P<0.05),而组间同期比较则均无统计学意义(P>0.05);两组QLQ-STO22评分均较治疗前有显著下降,且S组明显低于同期X组,差异均有统计学意义(P<0.05)。Log Rank检验结果显示,两组PFS比较均无统计学意义(P>0.05)。治疗6个周期内,两组胃肠道症状、血液和淋巴系统症状严重程度比较均无统计学意义(P>0.05),而S组手足综合征严重程度明显轻于X组(P<0.05)。结论SOX方案应用于术后复发性胃癌患者化疗能取得与XELOX方案相似疗效,但前者造成手足综合征程度较轻,有利于改善患者生活质量。Objective To explore the difference of blood tumor markers level,survival time and tolerance in patients with recurrent after gastric cancer treated withtegafur(S-1)/oxaliplatin(SOX)and Xeloda/oxaliplatin(XELOX)chemotherapy regimen.Methods The clinical data of 192 patients with recurrent gastric cancer after surgery were retrospectively analyzed.Patients with SOX regimen were included in group S(n=98),and patients with XELOX were included in group X(n=94).The serum tumor markers[carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA)]and quality of life[Quality of Life Questionnaire of Stomach 22(QLQ-STO22)]were compared before treatment and after 6 cycles of treatment.And the treatment effects[Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1)],progression-free survival(PFS),and severity of toxic and side effects within 6 cycles were analyzed in the two groups.Results After 6 cycles of treatment,there were no significant differences in ORR and mortality rate between the two groups(P>0.05).The serum levels of CA125,CA19-9 and CEA in the two groups were significantly lower than those before treatment(P<0.05),and there were no significant differences between the two groups(P>0.05).The QLQ-STO22 scores in the two groups were significantly lower than those before treatment,and the score in group S was significantly lower than that in group X(P<0.05).Log Rank test results showed that there were no significant differences in PFS between the two groups(P>0.05).Within 6 cycles of treatment,there were no significant differences in the severity of gastrointestinal symptoms,blood and lymphatic symptoms between the two groups(P>0.05),and the severity of hand-foot syndrome in group S was significantly lighter than that in group X(P<0.05).Conclusion SOX regimen in the chemotherapy of patients with recurrent gastric cancer after surgery can achieve similar efficacy with XELOX regimen.However,the former one has lighterseverity of hand-foot syndrome and is beneficial to improve pat

关 键 词：替吉奥 奥沙利铂 卡培他滨 复发 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]